Project Grant R01DA062274
Award Date
4/15/25
Completion Date
1/30/30
Dollars Obligated
$441K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Nebraska, USA
Similar Awards
This $714,783 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a comprehensive research initiative to investigate the intersection of HIV infection and opioid use on inflammasome activation, neuroinflammation, and neurotoxicity. The project will employ neuropathology, ex vivo, and in vitro methodologies to analyze brain tissue samples from persons with and without HIV, and with varying...
This $844,946 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to investigate the epigenetic regulation of inflammasome activation and its modulation by cannabinoids during chronic SIV infection and cocaine use. Specifically, the research will: Examine the epigenetic mechanisms underlying cannabinoid-mediated reduction of cocaine-induced inflammasome activation in blood monocytes, brain, and...
This $263,119 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop new NLRP3 inhibitor compounds to treat HIV-associated neuroinflammation in patients who also use cocaine. The key products and services to be delivered include: 1) computer-assisted design, synthesis, and characterization of new AMS-17 analogue compounds to improve biological activity and maintain low toxicity; and 2) in...
This Project Grant award of $983,672.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to provide unparalleled insight into the nature and extent of HIV and methamphetamine use in the brain, as well as the host-immune factors that facilitate inflammation and brain injury. The key products and services to be delivered under this award include the development and implementation of innovative single-cell...
This $3,472,327 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to study the impact of poly-substance use on the crosstalk between microglia, astrocytes, and neurons that regulates HIV latency. Led by Case Western Reserve University, the project will utilize newly developed methods to derive authentic microglia, astrocytes, and neurons from induced pluripotent stem cells (iPSCs) to investigate...
This $695,250 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the role of endothelial injury and myeloid cell migration in the activation of inflammasomes in HIV infection and cocaine exposure. The research, led by Howard University, aims to characterize myeloid cell populations in the brains of HIV-transgenic mice under chronic cocaine treatment, and evaluate the accumulation of...
This federal Project Grant award, valued at $5,147,311 and issued by the National Institute on Drug Abuse (NIDA, CFDA 93.279 - Drug Use and Addiction Research Programs), supports research to investigate the impact of HIV infection and cocaine use on the integrity of the blood-brain barrier (BBB) in people living with HIV (PLWH). The key objectives are to: 1) Determine how immune cell phenotypes and HIV proviral DNA burden in monocytes and T cells contribute to BBB permeability in PLWH with and...
This $1,537,749 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the molecular mechanisms underlying HIV and methamphetamine-induced neuroinflammation mediated by the astrocyte-specific NLRP6 inflammasome. The research, conducted at the University of Nebraska Medical Center (UNMC), uses in vitro, ex vivo, and in vivo approaches to elucidate how exposure to HIV Tat protein and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to elucidate the corticolimbic circuit and neuroimmune mechanisms underlying the comorbidity of HIV and cocaine use disorders. The $157,568 award, effective from November 13, 2024 to June 30, 2026, will be used by Drexel University to conduct studies that utilize circuit-specific optogenetics and chemogenetics to understand how HIV infection and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,717,777 in funding to the Icahn School of Medicine at Mount Sinai to investigate the impact of nicotine and HIV-1 infection on neuroinflammation and cognitive decline. The research aims to elucidate the role of the NLRP3 inflammasome in HIV-1-associated inflammation, with the goal of identifying potential therapeutic targets to address cognitive...